Aurora Cannabis faces a potential Curaleaf takeover at a 45% premium, but investors must weigh the offer against ACB's standalone prospects.
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to a loss of $0.19 per share a year ago.
Aurora Cannabis' shares plunge 28% in three months as a cautious fiscal 2027 outlook overshadows record medical cannabis growth and global expansion.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 23,915 | $66,719 | $71,505.85 | $4,786.85 | 7.17% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3,277 | $11,337.35 | $11,420.34 | $82.99 | 0.73% |
| NA Nizar Araji National Bank Of Canada /FI/ | 270,463.6 | $927,032.57 | $803,276.89 | -$123,755.68 | -13.35% |
| BR Bill Reuther SILVER OAK SECURITIES Inc.ORPORATED | 37,223 | $174,986.13 | $111,296.77 | -$63,689.36 | -36.4% |
Point72 Asset Management LP Point72 Asset Management LP | 10,665 | $30,104 | $39,300.52 | $9,196.52 | 30.55% |
| Specialty Retail Industry | Consumer Discretionary Sector | Miguel Martin CEO | NASDAQ (CM) Exchange | 05156X850 CUSIP |
| CA Country | 1,028 Employees | 11 May 2020 Last Dividend | 20 Feb 2024 Last Split | 11 Jul 2014 IPO Date |
Aurora Cannabis Inc. is a leader in the global cannabis industry, engaging in the production, distribution, and sale of cannabis and its derivatives across Canada and international markets. The company operates through three core segments: Canadian Cannabis, European Cannabis, and Plant Propagation. Its strategies include not only addressing the medical and consumer cannabis markets in Canada but also distributing wholesale medical cannabis throughout the European Union, various international regions such as Australia, the Caribbean, South America, and Israel, and providing supply for propagated vegetables and ornamental plants in North America. Furthermore, Aurora Cannabis extends its presence into the distribution and sale of hemp-derived CBD products. Based in Edmonton, Canada, the company has carved out a competitive position in the global landscape by focusing on diverse product offerings and comprehensive patient counseling and outreach services.
Aurora Cannabis produces a range of consumables including dried cannabis, cannabis oils, and capsules. These products are designed for multiple modes of consumption such as smoking, vaporizing, or ingestion in oil, capsule, or edible form. Each method offers a distinctive experience tailored to consumer and medical patient preferences.
The company's portfolio includes edible cannabis products, extracts, and soft gels. These products provide alternatives for those preferring not to inhale their cannabis, offering a variety of potencies and formulas to suit a diverse client base with specific needs.
Aurora's recreational cannabis products span categories such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products. These offerings fall under brands like Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, enabling Aurora to cater to a broad range of consumer tastes and preferences.
With a focus on patient needs, Aurora offers medical cannabis products under brands such as MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. These products are developed to support patients with specific therapeutic needs, ensuring high quality and efficacy.
Aurora distributes and sells a variety of hemp-derived CBD products, including brands like Reliva and KG7. These products cater to the growing demand for non-psychoactive cannabinoid products, offering benefits without the high associated with THC.
Beyond physical products, Aurora Cannabis extends its services to include patient counseling and outreach. This service demonstrates Aurora's commitment to the well-being of its customers, providing valuable information, support, and guidance on the use of cannabis for medical purposes.